Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual 64Cu-DOTATATE and 18F-FDG PET/CT in GEP-NEN
NCT05709171Phase 2Enrolling by invitation
- Sponsor
- Rigshospitalet
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Rigshospitalet. Primary endpoint: Progression Free Survival at 12 months. Started Jan 2023; status: enrolling by invitation.
Beyond the preview
Go deeper on NCT05709171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709171.